Bronchial asthma is a chronic inflammatory disease affecting the bronchial mucosa. In asthma patients, the highest number of inflammatory cells, including eosinophils, are found in the small bronchi. According to the most recent 2006 report of the Global Initiative for Asthma, inhaled corticosteroids (ICS) remain the first-line treatment of chronic asthma. They are characterized by high lung deposition and good distribution in the small bronchi, which makes them particularly efficient in reducing chronic inflammatory infiltrate in the small airways. Good pulmonary distribution of ICS in patients with mild asthma is reflected by a better control of the disease, improvement in the quality of life, improvement in the results of pulmonary function tests, decreased levels of exhaled proinflammatory nitric oxide, lower number of inflammatory cells (including eosinophils) in the induced sputum, decrease in bronchial hyperreactivity, and decrease in exhaled air trapping observed in the computed tomographic scanning of the lungs.
Small bronchi -peripheral airways Small bron chi are often referred to in the scientific litera ture as peripheral or small airways. They consti tute the largest part of the respiratory system and, therefore, the largest potential site of in flammation in patients with asthma and chron ic obstructive pulmonary disease.
1 Small bron chi and bronchioles of 2 mm in diameter are lo cated starting from the fourth down to the four teenth subdivision of the bronchial tree; thus, the total respiratory surface of the peripheral air ways is significantly increased.
2 In patients with asthma characterized by eosinophilic inflamma tion of the mucosa, the highest number of eo sinophils are found in the small bronchi. More over, involvement of the small bronchi in chron ic inflammation usually translates into increased bronchial hyperreactivity, 3 more severe course of the disease, poor asthma control, and decrease in the quality of life.
4,5
In line with the most recent report of the Glob al Initiative for Asthma (GINA), which was pub lished in 2006 and updated over the next several years, 6 disease severity no longer serves as a para meter for planning treatment strategy and has been replaced by the degree of control of the dis ease. The GINA report classifies patients into those with well controlled, partly controlled, and uncontrolled asthma. Inhaled corticosteroids (ICS) remain the firstline treatment in chronic asthma.
6-9 A prescribed amount of a given ICS is based on the level of asthma control and, what follows, on the degree of inflammation, partic ularly in the peripheral airways. Initial treat ment should include an inter mediate dosage of ICS and, subsequently, should be modified ac cording to the achieved level of control. 10 Lack of response to ICS in severe asthma can signal changes in the expression of glucocorticoid re ceptor, impaired Tcell reactivity, and disturbed immunoregulation. 11
Asthma-related inflammatory infiltrate in the small bronchi The pathogenesis of asthma involves chronic inflammation 6,8 mediated by migrato ry cells and structural cells releasing several
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Effect of inhaled corticosteroids on small airway inflammation in patients with bronchial asthma assumed that the response to the standard an tiinflammatory treatment with corticosteroids may depend on the diagnosed phenotype. It se ems that eosinophilic inflammation is the one that is characterized by the best response to cor ticosteroid treatment.
The comparison of inflammatory infiltrate be tween the large and small bronchi is difficult due to their varying para meters and architecture. 1 A number of studies suggested that inflammatory infiltrate is much more pronounced in the small airways than in the large bronchi, while others claimed that there is no difference or even that the opposite is true, i.e., the infiltrate in the small airways is less evident. 25 ), the most reliable para meter in assessing bronchoconstriction 1 3 the ratio of FVC to residual volume 4 dynamic lung compliance 5 closing volume (rarely used today).
Concentration of nitric oxide in expired air (fractional exhaled nitric oxide) as an indirect method of assessment Chemiluminescence is used as the most common method of detecting nitric oxide (NO) in the exhaled air. NO is a known mediator of in flammation and its presence in the exhaled air is a marker of an ongoing inflammatory process of the bronchial mucosa in asthma, lack of disease control, or exacerbation of the disease. Moreover, regular use of ICS in patients with asthma results in decreased fractional exhaled NO (FE NO ) . Mea surement of NO as a marker of ongoing bronchi al inflammation is a rather sensitive method, and the use of certain mathematical formulas can po tentially allow us to distinguish between alveolar and bronchial air. FE NO is a derivative of several contributors, including those that can be inde pendent of the presence of eosinophilic inflam matory infiltrate in the airways. Increased reactivity to nonspecific stimuli sug gests an ongoing bronchial inflammation. The test is considered to be positive when the inhalation of a nonspecific triggering substance results in a decrease of the forced expiratory volume in 1 proinflammatory mediators upon activation. Eo sinophils, neutrophils, lymphocytes, macrophag es, mast cells, epithelial cells, endothelial cells, smooth muscle cells, and fibroblasts all play their role in this process. Traditionally, eosinophils have been considered to be the main mediators of inflammation in asthma and to be responsible for epithelial damage, shedding of the bronchi al mucosa, remodeling and fibrosis. Eosinophils are the source of a number of cytokines, including inter leukin 5 (IL5) and granulocytemacrophage colonystimulating factor, which promote differ entiation of bone marrow stem cells into eosino phils. Several other cytokines produced and re leased by eosinophils contribute to bronchial in flammation in asthma: inter leukins (IL11, IL13, IL2, IL4), eicosanoids (leukotriene C 4 , prosta glandin E 2 , thromboxane B 2 , 15hydroxyeicosa tetraenoic acid), inter feronγ (INFγ), tumor ne crosis factor (TNF), and transforming growth factor β, which is involved in promoting fibrosis. Nevertheless, recent studies involving the anal ysis of mucosal bio psies, bronchoalveolar lavage (BAL), and induced sputum have indicated that eosinophilic inflammation is not the only possi ble scenario here; in some cases, the cellular infil trate is predominantly populated by neutrophils, a type of granulocytes responsible for fighting in fection. They constitute the main source of IL8, a chemokine with an ability to attract granulo cytes, and leukotriene B 4 , eicosanoid attracting and activating neutrophils. Neutrophils express receptors for immunoglobulin E as well as HLA class I and II molecules; therefore, they can po tentially present antigens as well as initiate and modulate an allergic immune response in patients with asthma exacerbated by simultaneous viral infection. Activated helper T cells are particular ly important in orchestrating allergic inflamma tory process in the bronchial mucosa. Depending on the pattern of produced cytokines, they can be divided into Th1 (IL2, IFNγ, TNF, IL12) and Th2 (IL4, IL5, IL3, IL13) cells.
According to the classification published in 2007, 12 all cases of asthma can be divided into 4 phenotypic entities depending on the composi tion of the inflammatory infiltrate, determined on the basis of cellular composition of induced spu tum. The values for healthy individuals are <1.9% for eosinophils and <61% for neutrophils.
Phenotypes of asthmatic inflammation are listed below: 1 eosinophilic: >1.9% eosinophils, <61% neu trophils 2 mixed >1.9% eosinophils, >61% neutrophils 3 neutropilic <1.9% eosinophils, >61% neutro phils 4 paucigranulocytic <1.9% eosinophils, <61% neutrophils.
Eosinophilic phenotype is the most common, and strictly correlates with atopy, bronchial hy perreactivity, and disease exacerbations. Altho ugh currently there is no unequivocal evidence supporting this hypothesis, it has been broadly usually
Level of deposition of inhaled corticosteroids in the small bronchi Distribution of ICS in the lung, and especially their deposition in the small bronchi, is particularly important for good asthma control and for the improvement of the quality of life. 18 In humans, the diameter of small bronchi is be low 2 mm, while their inner surface increases in a linear manner with each subsequent division. Due to the anatomical conditions (and without even mentioning the fact that the activity of al lergic inflammation is the highest in the periph eral bronchi) corticosteroid inhalers should be di rected predominantly to the periphery. Pulmo nary deposition and distribution of the ICScon taining aerosol depends on the presence of small, dispersed molecules in the total volume of re leased medication.
It has been proved that the most efficient deliv ery of the inhaled medication to the small airways can be achieved using metereddose/hydrofluo roalkane inhalers. They produce aerosol of which 50% are droplets smaller than 1.1 µm. Such drop lets have the highest capacity to travel through the anatomical throat barrier (high value of to tal pulmonary deposition) and are characterized by high potential to be deposited in the bronchi smaller than 2 mm (high deposition in the small bronchi) and deliver a potent ICS exactly where it can exert its antiinflammatory action.
Ciclesonide is an inhaled glucocorticoid (1.1-2.1 µm), characterized by high availabili ty for the small bronchi and, therefore, by high antiinflammatory efficiency. In an inhaler, it is present as a bio logically inactive prodrug with out the ability to bind the glucocorticoid recep tor, and is diluted in a freonfree carrier, hydro fluoroalkane. As much as 65% of the drug leav ing the inhaler during its administration reach es the lungs, 10% is removed from the periph eral airways while exhaling, and the remaining 55% is deposited in the respiratory system. Cicle sonide is highly lipophilic and therefore deposit ed in the lungs in a prompt and uniform manner. In the airways, prodrug becomes enzymatically cleaved to desciclesonide (desCIC), a derivative characterized by potent antiinflammatory prop erties. Subsequently, desCIC reaches the blood stream where it is almost entirely bound to plas ma proteins. Approximately 1% of the active drug reaches the peripheral tissues and organs as a free fraction. The level of deposition and the amount of active drug reaching the small bronchi deter mine its efficiency in limiting the ongoing inflam mation as well as achieving a prolonged period of remission/amelioration.
19-21
Direct evidence points to the exceptionally good deposition and distribution of ciclesonide, partic ularly in the peripheral airways. 22 In a study on second (FEV 1 ) by 20% or more as compared with the baseline value. A provocation dose PD 20 or provocation concentration PC 20 is established as a dosage of methacholine or adenosine that leads to a 20% decrease in the FEV 1 value. Although a popular diagnostic tool, it is not specific and re flects inflammation process not only in the small but also in the large bronchi. 1
Cyto logical examination of late-phase induced sputum
In the first (induction) stage of this test, sputum is collected after nebulizing with the saline or hy perosmolar sodium chloride solution. In the sec ond stage, sputum is processed and: 1) cytospin slides are prepared to assess the cellular compo nents and 2) remaining supernatant is tested for soluble pro and antiinflammatory mediators. Methodology of the test and the following anal ysis of the sputum should strictly follow the Eu ropean Respiratory Society guidelines published in the European Respiratory Journal in 2002, 13 and those of the Polish Society of Lung Diseases pub lished in 2008. 14 A thorough cyto logical analysis of latephase induced sputum enables differentia tion between various asthma phenotypes accord ing to the predominant cell type within the infil trate, e.g., eosinophils, neutrophils, or other cells. Sputum obtained in this method is usually de rived from the central bronchi.
oscillometric measurement of pulmonary resistance
Oscillometry assesses the changes in gas flow through the airways induced by a known vary ing external pressure. It measures the para meter of impedance, which consists of two elements re flecting the relationship between pressure and flow: resistance and reactance. While resistance is mainly dependent on unobstructed airways, re actance reflects pulmonary elasticity.
15 Impulse oscillometry system (IOS) and forced oscilla tion technique are the two most common meth ods for assessing bronchospasm and bronchial hyperreactivity. 15, 16 High-resolution computed tomography of the chest High resolution computed tomography is cur rently the most precise imaging technique able to visualize the pulmonary tissue. Selecting ap propriate para meters and adjusting the window of inter pretation allows to determine the thick ness of the bronchial wall, potential remodeling process, as well as expiratory lung volume (expira tory lung volume computed tomography). Dimin ished expiratory lung volume can be a sign of "air trapping", namely, an increased volume of residu al air and subsequent distention of the lung due to bronchoconstriction. 17 Importantly, bronchial wall remodeling always has to be considered while assessing potential bronchial obturation.
bronchoscopy Various cytokines as well as pro and antiinflammatory mediators can be easily detected in the epithelial lining fluid and the BAL fluid. 17 Similarly to the induced sputum, BAL (R5-R20, P <0.05), distal reactance (X5, P <0.01), reactance area (AX, P <0.01) and decreased levels of sputum eosinophils (P <0.01). Several publications underline the benefi cial antiinflammatory effects of ICS, especially ciclesonide, 28,29 but also of fluticasone. 28 Impor tantly, they inhibit or decrease the development of early and late phases of the allergeninduced bronchospasm, limit the extent of the inflam matory infiltration of the bronchi by decreasing the number of inflammatory cells, especially eo sinophils and lymphocytes, and act to prevent fu ture remodeling of the bronchial wall.
Conclusions Deposition of the drug in the small bronchi and its resulting local availability influ ence the efficiency of its antiinflammatory effects and its pharmacodynamics. Ciclesonide seems to fulfill all the criteria of being the drug of choice for patients with mild asthma; currently, it has one of the best deposition patterns compared with placebo 17, 30 or other ICS. 26, 27 Furthermore, it improves the chances of achieving better dis ease control, improves the quality of life, increases the values of pulmonary function tests, decreas es the levels of proinflammatory NO in the ex haled air, decreases the number of cells in the in flammatory infiltrate, including eosinophils, de creases the bronchial hyperreactivity by increas ing the PD 20 , and decreases the expiratory air trapping observed in the computed tomograph ic scanning of the lungs.
REfEREnCES
healthy volunteers, lung deposition of 99m Tcla belled ciclesonide was significantly higher than its deposition in the mouth and throat (52% vs. 32%, respectively). Moreover, the average percentage of drug deposited in the peripheral airways in cluding alveoli was higher than in the large bron chi (47% vs. 17%, respectively). Twodimensional (2D) gamma scintigraphy and threedimensional singlephoton emission computed tomography were used to measure deposition of ciclesonide in the lungs, bronchi, mouth, and throat. Pharma cokinetics of ciclesonide and its active meta bolite (desCIC) was analyzed using liquid chromato graphytandem mass spectrometry. Concentration of both substances was measured in mouthrins ing solutions. The pharmacokinetic profile of both Tclabeled and unlabeled ciclesonide was similar. 23 The drug was administered through hydrofluoro alkanemetered dose inhaler.
A similar study was conducted in 12 patients diagnosed with mild asthma with the mean FEV 1 values of approximately 95%. After a single in haled 320 µg dose of 99m Tclabeled ciclesonide, the deposition and distribution of the drug was measured by 2D gamma scintigraphy. Ciclesonide deposition was significantly higher in the lungs than in the mouth and throat (52% vs. 32.9%, respectively). 24 Additionally, ciclesonide has been reported to be well tolerated in children and to improve spirometric values and the quality of life of the patients while administered by a me tereddose inhaler with or without a spacer. 25 Efficiency of inhaled corticosteroids in small airway inflammation in asthma Antiinflammatory effect of ciclesonide (80 or 160 µg/daily in a single dose) was compared with the effect of 100 µg/daily in a single dose of fluticasone in patients with mild asthma. 26 Regardless of the dosage, after 2 weeks of therapy with ciclesonide, there was a signifi cant decrease in the level of NO in the expired air as compared with fluticasone. Such strong effect was not observed in the group treated by fluti casone even after 8 weeks of inhalation therapy, suggesting more potent antiinflammatory ac tion of ciclesonide. Nevertheless, the FEV 1 values and clinical symptoms improved and the use of fastacting β 2 mimetics on demand was reduced in all study groups, regardless of the adminis tered glucocorticoid.
A further analysis of ciclesonide's ability to lim it the inflammatory process in the small bronchi was described in a study published recently by Hoshino.
27 Patients with mild asthma were ad ministered either fluticasone (100 µg twice a day) or ciclesonide (200 µg once daily) for 8 consecu tive weeks. IOS and the measurement of eosino phil percentage in induced sputum were used to assess inflammatory process in the small air ways. A decrease or elimination of the inflamma tory process in the small airways was significantly more pronounced in the group treated with cicle sonide compared with fluticasone, as indicated by a significant decrease in small airway resistance
